NASDAQ: HSDTHelius Medical Technologies Inc Stock
$4.44-0.38 (-7.88%)
Updated Apr 25, 2024
HSDT Price
$4.44
Fair Value Price
$4.08
Market Cap
$3.94M
52 Week Low
$4.29
52 Week High
$14.44
P/E
-0.3x
P/B
1.68x
P/S
7.59x
PEG
N/A
Dividend Yield
N/A
Revenue
$644.00k
Earnings
-$8.85M
Gross Margin
9.5%
Operating Margin
-1,414.13%
Profit Margin
-1,374.2%
Debt to Equity
2.27
Operating Cash Flow
-$10M
Beta
0.69
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A
HSDT Overview
Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. Its product, Portable Neuromodulation Stimulator (PoNS), is a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company is headquartered in Newtown, Pennsylvania.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how HSDT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
HSDT ($4.44) is overvalued by 8.79% relative to our estimate of its Fair Value price of $4.08 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
HSDT ($4.44) is not significantly undervalued (8.79%) relative to our estimate of its Fair Value price of $4.08 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
HSDT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more HSDT due diligence checks available for Premium users.
Be the first to know about important HSDT news, forecast changes, insider trades & much more!
HSDT News
Valuation
HSDT fair value
Fair Value of HSDT stock based on Discounted Cash Flow (DCF)
Price
$4.44
Fair Value
$4.08
Overvalued by
8.79%
HSDT ($4.44) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
HSDT ($4.44) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
HSDT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
HSDT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.3x
Industry
29.73x
Market
40.97x
HSDT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.68x
Industry
3.71x
HSDT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
HSDT's financial health
Profit margin
Revenue
$134.0k
Net Income
-$1.0M
Profit Margin
-779.9%
HSDT's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
HSDT's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$7.7M
Liabilities
$5.3M
Debt to equity
2.27
HSDT's short-term assets ($7.44M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
HSDT's short-term assets ($7.44M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
HSDT's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
HSDT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.0M
Investing
-$3.0k
Financing
$622.0k
HSDT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
HSDT vs Medical Device Stocks
Helius Medical Technologies Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.